Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | OGA | O60502 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384882 | 1.00 | KMT2A (1.00) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL23652794 | 0.86 | MEN1 (0.76) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7756335 | 0.82 | RAB9A (0.74) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7760900 | 0.81 | RAB9A (1.00) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7959699 | 0.81 | RAB9A (0.71) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6905577 | 0.80 | MEN1 (0.66) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL7963191 | 0.79 | RAB9A (0.81) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7761263 | 0.79 | RAB9A (0.81) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27645188 | 0.78 | RAB9A (0.75) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7760033 | 0.78 | RAB9A (0.79) | KMT2AMEN1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011126937-A1 | TARGETED INTRACELLULAR DELIVERY OF OLIGONUCLEOTIDES VIA CONJUGATION WITH SMALL MOLECULE LIGANDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-10-13 | — | — | WO | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| WO-2024044355-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114340631-A | Combination for reducing serum phosphate in a patient | 阿德利克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1423103-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF DARPP-32 PHOSPHORYLATION | THE ROCKEFELLER UNIVERSITY (US) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003014321-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF DARPP-32 PHOSPHORYLATION | THE ROCKEFELLER UNIVERSITY (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | KMT2A 257/4885MEN1 4090/4885CYP1A2 4835/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | KMT2A 4666/4885MEN1 2203/4885CYP1A2 3929/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | KMT2A 4139/4885MEN1 2648/4885CYP1A2 4678/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | KMT2A 1331/4885MEN1 4080/4885CYP1A2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.